Stock Market News3 months FDA Accepts SNY and REGN’s Dupixent Re-Submitted sBLA for Urticaria Zacks
The FDA is set to give its decision on SNY and REGN’s sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
XThe FDA is set to give its decision on SNY and REGN’s sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
X